Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms
NCT03924856
active not recruiting
Enrollment Count
907
ACTUAL
Enrollment Rate
High
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
Memorial Sloan Kettering Cancer Center
Urinary Bladder Neoplasms
NCT03520491
recruiting
Enrollment Count
45
ESTIMATED
Enrollment Rate
Low
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
Sun Yat-sen University
Urinary Bladder Neoplasms
NCT05975307
not yet recruiting
Enrollment Count
64
ESTIMATED
Enrollment Rate
Low
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms
NCT03924895
recruiting
Enrollment Count
857
ESTIMATED
Enrollment Rate
High
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
Hoffmann-La Roche
Urinary Bladder Neoplasms
NCT04660344
recruiting
Enrollment Count
520
ESTIMATED
Enrollment Rate
High
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Masonic Cancer Center, University of Minnesota
Urinary Bladder Neoplasms
NCT03294304
completed
Enrollment Count
43
ACTUAL
Enrollment Rate
Low
a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
Yonsei University
Urinary Bladder Neoplasms
NCT04686149
not yet recruiting
Enrollment Count
39
ESTIMATED
Enrollment Rate
High
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Urinary Bladder Neoplasms
NCT04383743
recruiting
Enrollment Count
17
ESTIMATED
Enrollment Rate
Low
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
Urinary Bladder Neoplasms
NCT05581589
recruiting
Enrollment Count
18
ESTIMATED
Enrollment Rate
Low
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
AstraZeneca
Urinary Bladder Neoplasms
NCT03459846
active not recruiting
Enrollment Count
154
ACTUAL
Enrollment Rate
Medium